

■ Accreditation

Mount Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Mount Sinai designates this educational activity for a maximum of 14 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

■ Psychology Credit

The University of Miami Leonard M. Miller School of Medicine is approved by the American Psychological Association to sponsor continuing education for psychologists. The University of Miami Miller School of Medicine maintains responsibility for this program and its content.

14 CE credits will be awarded to psychologists for attendance at this conference.

■ Disclosure Statement

Faculty relationship(s) with industry will be disclosed and available in the Symposium Syllabus and at the meeting site. Disclosure to the audience will be made by the Faculty prior to their presentations by the Activity Director.

As a provider accredited by the Accreditation Council for Continuing Medical Education, Mount Sinai Medical Center requires its staff, and CME Committee members (i.e. Planners) to disclose to all stakeholders and learners that the individual either has or does not have Relevant Financial Relationship(s) with a commercial interest. Therefore, anyone in a position to control CME content must complete a Disclosure of Financial Relationship form. Planner relationship(s) with industry will be disclosed and available in the Symposium Syllabus.

■ Corporate Support

This symposium is made possible by unrestricted educational grants from industry; our appreciation is expressed for their support of this program. Sponsors will be listed in our Symposium Syllabus and on the Symposium Web-Site.

■ Acknowledgment

This symposium is being supported by the Florida Alzheimer's Disease Research Center (ADRC).

■ Symposium Information

Please contact: Warren Barker
MCI Symposium Coordinator
Wien Center for Alzheimer's Disease & Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2592 – Fax: 305-674-2996
E-mail: mcisymposium@msmc.com
Web: www.mcisymposium.org



Mount Sinai MEDICAL CENTER

Wien Center
4300 Alton Road
Miami Beach, FL 33140

Save the Date!

For information please contact:

Warren Barker

Phone: 305-674-2592

Email: mcisymposium@msmc.com

www.mcisymposium.org

MARK YOUR CALENDAR

6TH
ANNUAL

Mount Sinai
MEDICAL CENTER

MILD COGNITIVE IMPAIRMENT (MCI) SYMPOSIUM

"Theme for 2008: The Basis for Disease Modifying Treatments of Alzheimer's Disease"

Presented By:

The Wien Center for Alzheimer's Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach, Florida

and

The Johnnie B. Byrd, Sr. Alzheimer's Center & Research Institute
Tampa, Florida

Friday - Saturday, March 7-8, 2008

Symposium Location:

Miami Beach Resort & Spa

4833 Collins Ave., Miami Beach, FL 33140

Program Director:

Ranjan Duara, MD

Medical Director

Wien Center for Alzheimer's Disease & Memory Disorders

Mount Sinai Medical Center, Miami Beach, FL

Departments of Medicine and Psychiatry

Miller School of Medicine, University of Miami, Miami, FL

Sponsored By:

The Behrman Center for Medical Education
at Mount Sinai Medical center

■ Needs Assessment

Unless ways are found to prevent Alzheimer's Disease (AD) or delay its onset, it is projected that over 13 million people in the United States will be living with AD by 2050. Individuals with AD suffer from cognitive and functional impairment, loss of productivity and significant deterioration in over-all quality of life. Most will develop problematic behaviors, such as agitation and aggression, and many will need long-term care. In addition, caregivers of the patients are adversely affected by physical burden, emotional stress and financial hardship.

In the last two decades, significant progress has been made in understanding the pathogenesis of AD and the risk factors associated with the development of the clinical illness. This progress has stimulated the development of several potential disease modifying treatments for Alzheimer's disease. Advances in clinical neuropsychological assessment, brain imaging and biological markers have improved our ability to detect the disease earlier and monitor its progression with regards to treatment. Earlier detection and improved monitoring will become even more important as treatment options improve.

■ Target Audience

This activity is designed for:

- Neurologists
- Psychiatrists
- Geriatricians / Gerontologists
- Radiologists (neuroimaging specialists)
- Epidemiologists
- Neuropsychologists
- Psychologists
- Neuroscientists

■ Educational Objectives

The purpose of this series of symposia is to provide a forum for new information and for in-depth discussions about advances in Alzheimer's Disease (AD) research, clinical diagnosis and treatment. The goals of the Mild Cognitive Impairment (MCI) Symposium series are to study the pathophysiology of AD and other causes of dementia, and to explore possible methods of intervention in the earliest stages of these disorders, that is, in the MCI stage. In the current symposium we will examine recent developments in understanding disease mechanisms which offer potential strategies for treating and preventing Alzheimer's disease. We will also study methodologies for identifying the earliest stages of the disease as well as assessing the effects of treatment. Finally, we will present results from several studies on potential disease-modifying treatments for Alzheimer's disease that may become available in the future.

The symposium will include a keynote address, a panel discussion, and four individually themed symposia, each featuring national and international experts in the fields of neurology, neurobiology, psychiatry, geriatrics, neuropsychology, radiology, epidemiology and pharmacology. Each mini-symposium will be followed by an extended discussion period, allowing active audience participation to promote a better understanding of the issues.

Upon completion of this symposium, the attendees should have a better understanding of the following:

- Known Risk Factors for Alzheimer's Disease (AD)
- Determinants of the Rate of Progression of AD
- Pathogenic Mechanisms for Cognitive Impairment in Animals and Humans
- Measurement of the Progression and the Effects of Treatment in AD
- Why, When and How to Disclose the Diagnosis of AD
- Non-Pharmacological Treatment and Prevention of Early AD and other Dementias
- Potential Disease Modifying Agents for Treatment and Prevention of AD





Distinguished Faculty

Program Director

Ranjan Duara, MD

Medical Director, Wien Center for Alzheimer's Disease & Memory Disorders
Mount Sinai Medical Center, Miami Beach, FL
Departments of Medicine and Psychiatry, Miller School of Medicine
University of Miami, FL

Keynote Speaker:

Denis Evans, MD

Professor of Neurological Sciences
Rush University Medical Center
Chicago, Illinois

Distinguished Faculty:

Paul Aisen, MD

Professor of Neurology and Medicine
Director, Memory Disorders Program
Georgetown University Hospital
Washington, District of Columbia

Gary W. Arendash, PhD

Research Professor and Mouse Core Director
Johnnie B. Byrd Sr., Alzheimer's Center
& Research Institute
Tampa, Florida

Stephen Bondy, PhD

Professor, Department of Community
and Environmental Medicine
University of California
Irvine, California

Soo Borson, MD

Professor of Psychiatry and Behavioral
Sciences, University of Washington
School of Medicine
Director, Geriatric and Family Services
Clinic, University of Washington
Medical Center
Seattle, Washington

Carl Cotman, PhD

Director of the Institute for Brain Aging
and Dementia
Professor of Neurology and Psychobiology
University of California
Irvine, California

Karen Duff, PhD

Professor, Taub Institute
Department of Pathology
(Columbia University) and Psychiatry
(NYS Psychiatric Institute)
New York, New York

Laura Fratiglioni, MD, PhD

Professor, Director of the Aging
Research Center,
Karolinska Institutet
Stockholm, Sweden

Mary Ganguli, MD, MPH

Professor of Psychiatry and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Todd E. Golde MD, PhD

Chair, Professor and Consultant
Department of Neuroscience
Mayo Clinic Jacksonville
Jacksonville, Florida

Michael Grundman, MD, MPH

Senior Director of Clinical Development
in the Alzheimer's Disease Program
Elan Pharmaceuticals
San Francisco, California

Clifford R Jack, Jr, MD

Professor of Radiology, The Alexander Family
Professor in Alzheimer's Disease Research
Mayo Clinic and Foundation
Rochester, Minnesota

Angela L. Jefferson, PhD

Assistant Professor of Medicine
Co-Director, Boston University Alzheimer's
Disease Center Education & Information
Transfer Core
Boston University School of Medicine
Boston, Massachusetts

Arthur Kramer, PhD

Professor & Director of the Biomedical
Imaging Center
University of Illinois
Urbana, Illinois

David Loewenstein, PhD

Professor of Psychiatric &
Behavioral Sciences
University of Miami and The Wien Center
Miami Beach, Florida

Jose A. Luchsinger, MD MPH

Florence Irving Assistant Professor of
Medicine and Epidemiology
Columbia University
New York, New York

Professor Colin L. Masters, BMedSci(Hons), MBBS, MD, FRCPATH, FRCPA, FAA

Executive Director and Laureate Professor,
Mental Health Research Institute,
University of Melbourne
Victoria, Australia

JoAnne McLaurin, PhD

Professor, Centre for Research in
Neurodegenerative Diseases and
Department of Laboratory Medicine
and Pathobiology
University of Toronto, Toronto, Canada

Mary Mittelman, DrPH

Director of Psychosocial Research and
Support Program, Silberstein Institute
Research Professor, Department of Psychiatry,
NYU School of Medicine
New York, New York

John Morris, MD

Friedman Distinguished Professor of
Neurology
Washington University School of Medicine
St. Louis, Missouri

Ronald Petersen, MD, PhD

Professor of Neurology and Alzheimer
Disease Research
Mayo Medical School
Rochester, Minnesota

Michael J. Pontecorvo, PhD

Vice President, Clinical Research
Avid Radiopharmaceuticals
Philadelphia, Pennsylvania

Huntington Potter, PhD

CEO and Scientific Director
Johnnie B. Byrd Sr.,
Alzheimer's Center & Research Institute
Tampa, Florida

Orien Reid, MSW

Chairman, Alzheimer's Disease International
London, United Kingdom

Norman Relkin, MD, PhD

Associate Professor of Clinical Neurology
& Neuroscience
Weill Medical College of Cornell
New York, New York

Eric Rodriguez MD, MPhil

Associate Professor, Department of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Juan Sanchez-Ramos, PhD, MD

Helen E. Ellis Professor of Neurology
University of South Florida
Tampa, Florida

Eric Siemers, MD

Medical Director, Alzheimer's Disease Team
Lilly Corporate Center, Eli Lilly and Company
Indianapolis, Indiana

Gary W. Small, MD

Parlow-Solomon Professor on Aging
and Professor of Psychiatry
Director, UCLA Center on Aging
Los Angeles, California

Mike Weiner, MD

Director, Center for Imaging of
Neurodegenerative Diseases,
San Francisco VAMC
Professor of Medicine, Radiology,
Psychiatry, and Neurology
University of California
San Francisco, California

Robert S. Wilson, PhD

Rush Alzheimer's Disease Center
Rush University Medical Center
Chicago, Illinois

Philip A. Wolf, MD

Professor of Neurology & Principal
Investigator, the Framingham Heart Study
Boston University School of Medicine
Boston, Massachusetts

Kenton H. Zavitz, PhD

Senior Director of Clinical Affairs
Myriad Pharmaceuticals, Inc.
Salt Lake City, Utah

Friday, March 7, 2008

AM

- 7:00-8:00 Breakfast Buffet
- 8:00-8:15 Welcome and Introduction
Ranjan Duara MD
- 8:15-9:15 Keynote Address: **What Determines the Risk of and Rate of Progression in Alzheimer's Disease: Mechanisms and Modifiers**
Denis Evans, MD
- 9:15-11:15 Mini-Symposium: Pathogenic Mechanisms for Cognitive Impairment in Animals and Humans
Chair: Carl Cotman, PhD
- Amyloid Metabolism and Cognitive Impairment in Animals and Humans
Todd Golde, PhD
- Tau Pathology and Cognitive Impairment in Animals and Humans
Karen Duff, PhD
- Protein Misfolding in the Pathogenesis of AD
JoAnne McLaurin, PhD
- Inflammation and Brain Aging
Stephen Bondy, PhD
- Inflammatory Cytokines and Cognitive Impairment in Aging
Philip Wolf, MD
- Hypertension, Metabolic Syndrome and Cognitive Impairment
Jose Luchsinger, MD, MPH
- 11:15-11:30 Break
- 11:30-12:15 Open Discussion
- 12:15-1:30 LUNCH BREAK

PM

- 1:30-4:00 Mini-Symposium: **Biomarkers for Measuring Progression and the Effects of Treatment in AD**
Chair: Mike Weiner, MD
- Cognitive Measurement
Robert Wilson, PhD
- Volumetric MRI (the ADNI Experience)
Clifford Jack, MD
- 4 Tesla MRI in MCI and Early AD
Michael Weiner, MD
- Amyloid Imaging with [C-11] PIB in Normal Aging, MCI and AD
Colin Masters, MD, PhD
- Amyloid Imaging with [F-18] 1, 4-diphenyltriazoles
Mike Pontecorvo, PhD
- PET FDG and Amyloid and Tau Imaging with [F-18] FDDNP in Early AD
Gary Small, MD
- CSF Biomarkers in MCI and Early AD
John Morris, MD
- 4:00-4:15 Break
- 4:15-5:00 Open Discussion
- 5:30-7:00 Panel Discussion: Disclosing the Diagnosis: Why, When and How
Chair: Mary Ganguli, MD, MPH
Panelists (Ronald Petersen, MD, PhD; Angela Jefferson, PhD; Mary Mittelman, DrPH; Soo Borson, MD; Eric Rodriguez, MD; Orien Reid, MSW)
- 7:00-9:00 WELCOME DINNER

Saturday, March 8, 2008

AM

- 7:30-8:30 Breakfast Buffet
- 8:30-8:45 Announcements and Introductions
Ranjan Duara, MD
- 8:45-10:30 Mini-Symposium:
**Non-Pharmacological Treatment
and Prevention of Early AD and
Other Dementias**
Chair: Huntington Potter, PhD
- Hematopoietic Growth Factors
for Brain Repair
Juan Sanchez-Ramos, MD, PhD
- Risk Factors for Cognitive Decline
Laura Fratiglioni, MD, PhD
- Cognitive and Environmental Stimulation
for both Treatment and Prevention of
Alzheimer's Disease: Transgenic
Mouse Studies
Gary Arendash, PhD
- Cognitive Rehabilitation in MCI
and Early AD
David Loewenstein, PhD
- The Role of Exercise and Intellectual
Engagement on AD and Cognition of
older adults
Art Kramer, PhD
- 10:30-10:45 Break
- 10:45-11:30 Open Discussion
- 11:30-1:00 LUNCH BREAK

PM

- 1:00-3:00 Mini-Symposium: **Potential Disease
Modifying Agents for Treatment and
Prevention of AD**
Chair: Paul Aisen, MD
- Drug Development for AD and Prodromal
AD: an Overview
Paul Aisen, MD
- Clioquinol (Reformulated)
Colin Masters, MD
- Immunotherapy for AD
(Immunoglobulin Infusion)
Norman Relkin, MD, PhD
- Immunotherapy for AD (Antibody Infusion)
Michael Grundman, MD
- Flurizan: A Gamma Secretase
Modulating Agent
Kenton Zavitz, PhD
- LY450139: a Gamma secretase inhibitor
Eric Siemers, MD, PhD
- 3:00-3:15 Break
- 3:15-4:00 Open Discussion
- 4:00 Adjourn



Registration Information

■ Method of Registration

To register by mail or fax: please complete the registration form and send it with the payment to the above mailing address or fax number.

To register by internet:

www.mcisymposium.org

Registration confirmations will be issued.

Payment: Registration fees can be paid by credit card or check, no cash is accepted.

Please make all checks payable to
MOUNT SINAI MEDICAL CENTER

Registration Fee Inclusions: Registration fees include admittance to all the scientific sessions, conferences, conference materials, validated parking, breakfast, lunch, refreshment breaks and welcome dinner as specified in the program.

Registration Hours: The conference registration desk will be staffed:

Thursday, March 6 –

Mediterranean Foyer

4:00 pm – 7:00 pm

Friday, March 7 –

Meeting Room: Mediterranean East

7:00 am - 5:00 pm

Saturday, March 8 –

Meeting Room: Mediterranean East

7:00 am - 5:00 pm


■ Symposium Location

Miami Beach Resort and Spa:

4833 Collins Ave, Miami Beach, FL 33140

Phone: 1-866-767-6060

Web-Site: www.miamibeachresortandspa.com



A historic masterpiece on the water, the Miami Beach Resort & Spa features luxurious beachfront accommodations, breathtaking ocean views, and easy access to world-famous attractions, restaurants, and nightspots.

With the spectacular Atlantic Ocean and its beaches at your doorstep, enjoy the nearby world-class shopping and nightlife destinations of South Beach.

This distinctive hotel is surrounded by the Atlantic Ocean and the Intracoastal Waterway, and boasts 424

elegant guest rooms and suites – each brimming with thoughtful amenities such as high-speed Internet access and floor-to-ceiling oceanfront views. Visit our Beachfront Aqua Sports Center to prepare for a day of exciting jet skiing or parasailing. Drift to sleep under

the warm sunshine in a poolside cabana or on the white-sand beach nestled at your doorstep. If you can bear to leave our oceanfront Miami Beach resort, spend a day exploring world-class museums and trendy boutiques and salons, and when evening falls, indulge in the sizzling restaurants and nightclubs of South Beach, just down the street. Our alluring resort offers the ideal blend of South Beach sun and Miami cool, all in a picture perfect setting.



■ Hotel Reservations

For the convenience of the 6th Annual MCI Symposium attendees, a limited number of rooms have been reserved at the special daily rate of \$229.00 (single or double occupancy, plus resort fees, state and local taxes). To receive this conference rate, reservations must be made directly with the Miami Beach Resort and Spa and you must mention that you are a registrant of the 6th Annual MCI Symposium. Rooms will be held at the special rate until Monday, February 11, 2008. Rooms at the discounted rate will be allocated on a first-come, first-served basis. Reservations received after the cut-off date are subject to availability and prevailing rates.

FOR ROOM RESERVATIONS CALL: 1-866-767-6060 OR ACCESS THE HOTEL WEB SITE VIA www.miamibeachresortandspa.com or VISIT THE MEETING WEBSITE VIA www.mcisymposium.org

Business casual attire is appropriate for all events. A light sweater or jacket is recommended in the meeting rooms.

MILD COGNITIVE IMPAIRMENT (MCI) SYMPOSIUM

Registration Form

■ THREE EASY WAYS TO REGISTER

ONLINE:

www.mcisymposium.org

FAX:

Attn: Warren Barker
(305) 674-2996

MAIL:

Warren Barker
Mount Sinai
4300 Alton Road
Miami Beach, FL 33140

■ REGISTRANT INFORMATION Please print:

LAST NAME FIRST NAME MI

DEGREE: ☐ MD ☐ DO ☐ PhD ☐ PsyD ☐ OTHER

ADDRESS

CITY STATE ZIP CODE COUNTRY

E-MAIL FAX TELEPHONE

■ REGISTRATION FEES:

Physicians: Discounted: ☐ \$340.00 (if dated/postmarked by February 8)
☐ \$390.00 (if dated/postmarked after February 8)
☐ \$440.00 (on site registration)

Non-Physicians: Discounted: ☐ \$225.00 (if dated/postmarked by February 8)
☐ \$275.00 (if dated/postmarked after February 8)
☐ \$325.00 (on site registration)
☐ \$100.00 (students)

■ PAYMENT METHOD:

☐ American Express ☐ Master Card ☐ Visa ☐ Check in the amount of _____

Card No. _____ Expiration Date ____/____

Cardholder's Name _____

Signature _____

Payment must accompany registration form

Refund Policy: Full refund will be given if written notice is received not later than February 8, 2008.

All refunds will be processed after the meeting.